Genomics meets HIV-1

Nature Reviews Microbiology

Volumn 4, Issue 11, 2006, Pages 865-873

  Telenti, Amalio ^a   Goldstein, David B ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CX3C CHEMOKINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; INTERLEUKIN 4; PLACEBO; RANTES; RECOMBINANT GLYCOPROTEIN GP 120; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN;

ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE GENE MAPPING; DRUG DESIGN; DRUG RESEARCH; DRUG TARGETING; EVOLUTIONARY ADAPTATION; GENETIC ASSOCIATION; GENETIC IDENTIFICATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; MOLECULAR BIOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

AIDS VACCINES; CHROMOSOME MAPPING; CHROMOSOMES, HUMAN; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; GENOMICS; HAPLOTYPES; HIV INFECTIONS; HIV-1; HUMANS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33750122144     PISSN: 17401526     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrmicro1532     Document Type: Article

References (78)

1. Ioannidis, J. P. Commentary: Grading the credibility of molecular evidence for complex diseases. Int. J. Epidemiol. 35, 572-578 (2006).
2. O'Brien, S. J. & Nelson, G. W. Human genes that limit AIDS. Nature Genet. 36, 565-574 (2004).
3. Telenti, A. & Bleiber, G. Host genetics of HIV-1 susceptibility. Future Virol. 1, 55-70 (2006).
4. Bleiber, G. et al. Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the human immunodeficiency virus type 1 life cycle for variants influencing disease progression. J. Virol. 79, 12674-12680 (2005).
5. Todd, J. A. Statistical false positive or true disease pathway? Nature Genet. 38, 731-733 (2006).
6. Draenert, R. et al. Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J. Exp. Med. 203, 529-539 (2006).
7. Plummer, F. A., Ball, T. B., Kimani, J. & Fowke, K. R. Resistance to HIV-1 infection among highly exposed sex workers in Nairobi: What mediates protection and why does it develop? Immunol. Lett. 66, 27-34 (1999).
8. Chang, J. et al. Twin studies demonstrate a host cell genetic effect on productive human immunodeficiency virus infection of human monocytes and macrophages in vitro. J. Virol. 70, 7792-7803 (1996).
9. Ciuffi, A. et al. Entry and transcription as key determinants of differences in CD4 T cell permissiveness to HIV-1 infection. J. Virol. 78, 10747-10754 (2004).
10. Picard, C., Casanova, J. L. & Abel, L. Mendelian traits that confer predisposition or resistance to specific infections in humans. Curr. Opin. Immunol. (2006).
11. Risch, N. & Merikangas, K. The future of genetic studies of complex human diseases. Science 273, 1516-1517 (1996).
12. Altshuler, D. et al. A haplotype map of the human genome. Nature 437, 1299-1320 (2005).
13. Goldstein, D. B. & Cavalleri, G. L. Genomics: Understanding human diversity. Nature 437, 1241-1242 (2005).
14. Syvanen, A. C. Toward genome-wide SNP genotyping. Nature Genet. 37, S5-S10 (2005).
15. Barrett, J. C. & Cardon, L. R. Evaluating coverage of genome-wide association studies. Nature Genet. 38, 659-662 (2006).
16. Pe'er, I. et al. Evaluating and improving power in whole-genome association studies using fixed marker sets. Nature Genet. 38, 663-667 (2006).
17. Ahmadi, K. R. et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nature Genet. 37, 84-89 (2005).
18. Tsai, H. J. et al. Comparison of three methods to estimate genetic ancestry and control for stratification in genetic association studies among admixed populations. Hum. Genet. 118, 424-433 (2005).
19. Hahn, B. H., Shaw, G. M., De Cock, K. M. & Sharp, P. M. AIDS as a zoonosis: Scientific and public health implications. Science 287, 607-614 (2000).
20. Stremlau, M. et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature 427, 848-853 (2004).
21. Cullen, B. R. Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J. Virol. 80, 1067-1076 (2006).
22. Sharp, P. M., Shaw, G. M. & Hahn, B. H. Simian immunodeficiency virus infection of chimpanzees. J. Virol. 79, 3891-3902 (2005).
23. Hirsch, V. M. What can natural infection of African monkeys with simian immunodeficiency virus tell us about the pathogenesis of AIDS? AIDS Rev. 6, 40-53 (2004).
24. Silvestri, G. Naturally SIV-infected sooty mangabeys: Are we closer to understanding why they do not develop AIDS? J. Med. Primatol. 34, 243-252 (2005).
25. Schindler, M. et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 125, 1055-1067 (2006).
26. Foster, J. L. & Garcia, J. V. HIV pathogenesis: Nef loses control. Cell 125, 1034-1035 (2006).
27. Yang, Z. The power of phylogenetic comparison in revealing protein function. Proc. Natl Acad. Sci. USA 102, 3179-3180 (2005).
28. Voight, B. F., Kudaravalli, S., Wen, X. & Pritchard, J. K. A map of recent positive selection in the human genome. PLoS. Biol. 4, e72 (2006).
29. Sawyer, S. L., Wu, L. I., Emerman, M. & Malik, H. S. Positive selection of primate TRIM5α identifies a critical species-specific retroviral restriction domain. Proc. Natl Acad. Sci. USA 102, 2832-2837 (2005).
30. Sawyer, S. L., Emerman, M. & Malik, H. S. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS. Biol. 2, e275 (2004).
31. Ortiz, M., Bleiber, G., Martinez, R., Kaessmann, H. & Telenti, A. Patterns of evolution of host proteins involved in retroviral pathogenesis. Retrovirology 3, 11 (2006).
32. Mangeat, B. & Trono, D. Lentiviral vectors and antiretroviral intrinsic immunity. Hum. Gene Ther. 16, 913-920 (2005).
33. Yu, X.-F. Innate cellular defenses of APOBEC3 cytidine deaminases and viral counter-defenses. Curr. Opin. HIV/AIDS 1, 187-193 (2006).
34. Sheehy, A. M., Gaddis, N. C., Choi, J. D. & Malim, M. H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-650 (2002).
35. Mangeat, B., Turelli, P., Liao, S. & Trono, D. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279, 14481-14483 (2004).
36. Schrofelbauer, B., Chen, D. & Landau, N. R. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl Acad. Sci. USA 101, 3927-3932 (2004).
37. Reymond, A. et al. The tripartite motif family identifies cell compartments. EMBO J. 20, 2140-2151 (2001).
38. Nisole, S., Stoye, J. P. & Saib, A. TRIM family proteins: Retroviral restriction and antiviral defence. Nature Rev. Microbiol. 3, 799-808 (2005).
39. Towers, G. J. Restriction of retroviruses by TRIM5α. Future Virol 1, 71-78 (2006).
40. Stremlau, M. et al. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5α restriction factor. Proc. Natl Acad. Sci. USA 103, 5514-5519 (2006).
41. Stremlau, M., Perron, M., Welikala, S. & Sodroski, J. Species-specific variation in the B30. 2(SPRY) Domain of TRIM5α determines the potency of human immunodeficiency virus restriction. J. Virol. 79, 3139-3145 (2005).
42. Li, Y., Li, X., Stremlau, M., Lee, M. & Sodroski, J. Removal of arginine 332 allows human TRIM5α to bind human immunodeficiency virus capsids and to restrict infection. J. Virol. 80, 6738-6744 (2006).
43. Yap, M. W., Nisole, S. & Stoye, J. P. A single amino acid change in the SPRY domain of human TRIM5α leads to HIV-1 restriction. Curr. Biol. 15, 73-78 (2005).
44. Ohkura, S., Yap, M. W., Sheldon, T. & Stoye, J. P. All three variable regions of the TRIM5α B30.2 domain can contribute to the specificity of the retrovirus restriction. J. Virol. 80, 8554-8565 (2006).
45. Roach, J. C. et al. The evolution of vertebrate Toll-like receptors. Proc. Natl Acad. Sci. USA 102, 9577-9582 (2005).
46. Bashirova, A. A. et al. Novel member of the CD209 (DC-SIGN) gene family in primates. J. Virol. 77, 217-227 (2003).
47. Barreiro, L. B. et al. The heritage of pathogen pressures and ancient demography in the human innate-immunity CD209/CD209L region. Am. J. Hum. Genet. 77, 869-886 (2005).
48. Sambrook, J. G. et al. Single haplotype analysis demonstrates rapid evolution of the killer immunoglobulin-like receptor (KIR) loci in primates. Genome Res. 15, 25-35 (2005).
49. Walsh, E. C. et al. Searching for signals of evolutionary selection in 168 genes related to immune function. Hum. Genet. 119, 92-102 (2006).
50. Sabeti, P. C. et al. Positive natural selection in the human lineage. Science 312, 1614-1620 (2006).
51. Telenti, A. & Ioannidis, J. P. Susceptibility to HIV - disentangling host genetics and host behavior. J. Infect. Dis. 193, 4-6 (2006).
52. + T-cell depletion in simian HIV infection. J. Acquir. Immune. Defic. Syndr. 41, 259-265 (2006).
53. Pilcher, C. D. et al. Detection of acute infections during HIV testing in North Carolina. N. Engl. J. Med. 352, 1873-1883 (2005).
54. Lifson, J. D. et al. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J. Virol. 71, 9508-9514 (1997).
55. Mellors, J. W. et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann. Intern. Med. 122, 573-579 (1995).
56. Lambotte, O. et al. HIV controllers: A homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin. Infect. Dis. 41, 1053-1056 (2005).
57. Cohen, M. S. Thomas Parran Award Lecture: Transmission and prevention of transmission of HIV-1. Sex Transm. Dis. 33, 338-341 (2006).
58. Kaslow, R. A., Dorak, T. & Tang, J. J. Influence of host genetic variation on susceptibility to HIV type 1 infection. J. Infect. Dis. 191, S68-S77 (2005).
59. Mazzoli, S. et al. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals. Nature Med. 3, 1250-1257 (1997).
60. Marzolini, C., Kim, R. B. & Telenti, A. Pharmacogenetics of antiretroviral agents in AIDS Therapy (eds Dolin, R. Masur, H. & Saag, MS.) (Churchill Livingstone, 2006).
61. Colhoun, H. M., McKeigue, P. M. & Davey, S. G. Problems of reporting genetic associations with complex outcomes. Lancet 361, 865-872 (2003).
62. Freimer, N. B. & Sabatti, C. Guidelines for association studies in human molecular genetics. Hum. Mol. Genet. 14, 2481-2483 (2005)
63. Haas, D. W. et al. A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG Protocol A5128. HIV. Clin. Trials 4, 287-300 (2003).
64. Lieberman, J. Defying death - HIV mutation to evade cytotoxic T lymphocytes. N. Engl. J. Med. 347, 1203-1204 (2002).
65. Moore, C. B. et al. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296, 1439-1443 (2002).
66. Telenti, A., Beckmann, J. S. & Mallal, S. HLA and HIV: Modeling adaptation to moving targets. Pharmacogenomics J. 3, 254-256 (2003).
67. Trachtenberg, E. et al. Advantage of rare HLA supertype in HIV disease progression. Nature Med. 9, 928-935 (2003).
68. Carrington, M. & O'Brien, S. J. The influence of HLA genotype on AIDS. Annu. Rev. Med. 54, 535-551 (2003).
69. Chen, L., Perlina, A. & Lee, C. J. Positive selection detection in 40,000 human immunodeficiency virus (HIV) type 1 sequences automatically identifies drug resistance and positive fitness mutations in HIV protease and reverse transcriptase. J. Virol. 78, 3722-3732 (2004).
70. Yang, W., Bielawski, J. P. & Yang, Z. Widespread adaptive evolution in the human immunodeficiency virus type 1 genome. J. Mol. Evol. 57, 212-221 (2003).
71. van Opijnen, O. T. & Berkhout, B. The host environment drives HIV-1 fitness. Rev. Med. Virol. 15, 219-233 (2005).
72. Quinones-Mateu, M. E. & Arts, E. J. Virus fitness: Concept, quantification, and application to HIV population dynamics. Curr. Top. Microbiol. Immunol. 299, 83-140 (2006).
73. Gilbert, P. B. et al. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191, 666-677 (2005).
74. Montefiori, D. C. et al. Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J. Infect. Dis. 190, 1962-1969 (2004).
75. Evans, D. M. & Cardon, L. R. Genome-wide association: A promising start to a long race. Trends Genet. 22, 350-354 (2006).
76. Clark, A. G. Genomics of the evolutionary process. Trends Ecol. Evol. 21, 316-321 (2006).
77. Coordinating committee of the global HIV/AIDS vaccine enterprise strategy for developing an HIV vaccine. PLoS Med. 2, e35 (2005).
78. Telenti, A. Host polymorphism in post-entry steps of the HIV-1 life cycle and other genetic variants influencing HIV-1 pathogenesis. Curr. Opin. HIV/AIDS 1, 232-240 (2006).